Taiwanese vaccine manufacturer Adimmune Corp (國光生技) yesterday signed a cooperation pact with China-based Shenzhen Techdow Pharmaceutical Co Ltd (天道醫藥) to produce enoxaparin sodium injections, which are used to prevent and treat blood clots.
The cooperation would unite Adimmune’s aseptic ampoule-filling technology with Techdow Pharmaceutical’s enoxaparin sodium manufacturing technology, allowing the firms to produce injections that can pass the high standards set in Europe and the US.
The patent for the original blood clot prevention drug has expired, but it would be difficult to develop a new drug that is as effective, Techdow Pharmaceutical general manager Jake Li (李建科) said yesterday.
Each year, 100 million units of enoxaparin sodium injections are sold in the US market and 360 million in Europe. Sales are estimated to be about US$2 billion per year in both regions, Li said.
Adimmune will manufacture the product in local factories starting next year and is expected to be certified by the European Medicines Agency as a manufacturer of the injections by next year, chief financial officer Vic Chang (張哲瑋) said.
The two companies plan to manufacture 10 million units a year at first, and increase production volume to 50 million units within three to five years, he said.
Adimmune reported consolidated losses of NT$603.68 million (US$20.24 million) last year, 28 percent more than the NT$471.32 million loss it posted a year ago, which the company attributed to lower profit margins for flu vaccines.
The Greater Taichung-based company expects a better outlook for this year once another of its partnerts, Dutch biotech firm Crucell NV, receives more approvals to distribute Adimmune’s flu vaccines in Europe.
The company’s flu vaccines were approved for sale in Germany, the UK and Italy last year, and received the green light in Switzerland last month. The vaccines are currently being reviewed by other European countries, as well as the Pan-American Health Organization, Adimmune said.
“We are striving to swing to the black this year,” Chang said.
Adimmune chairman Steve Chan (詹啟賢) said the company is capable of producing between 5 million and 10 million units of a preliminary vaccine for H7N9 — a subtype of the avian influenza virus — within two months if the strain spreads beyond control, citing its extensive experience producing the vaccine for avian flu subtype H1N1.
Preliminary vaccines are used when a vaccine cannot be developed or manufactured in time to stop a sudden outbreak, Chan said, adding that there is currently no specific vaccine for H7N9.
Adimmune’s shares rose 6.97 percent to NT$40.65 yesterday, outperforming the TAIEX, which was up 0.18 percent.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by